Monthly Archives: February 2016

Gene therapy for osteoarthritis ?

GeneQuine develops drugs that are based on gene therapy. The concept of gene therapy is to introduce genetic material into the patient’s own cells in the body. The cells produce then a therapeutic protein according to the template that the introduced genetic material (DNA) provides

GeneQuine is focused on the development of gene therapy agents for the treatment of osteoarthritis. Osteoarthritis is a degenerative joint disorder characterized by cartilage loss and inflammation. Patients affected by osteoarthritis experience joint pain as well as swelling and stiffness of the joints leading to … Read more

Gene editing target disease ?

Genome Editing with CRISPR-Cas9

Here’s a short list of some common diseases that might be curable or preventable with gene editing:

Breast cancer
Colon cancer
Huntington’s disease
Marfan, Parkinson’s
Prostate cancer
Retinitis pigmentosa
Sickle cell
Skin cancer
Duchenne muscular dystrophy
Color blindness
Cystic fibrosis
Down syndrome
Polycystic kidney
Turner syndrome.

There are hundreds of other more rare genetic disorders.… Read more

Gene therapy for spinal muscular atrophy (SMA) Type 1


Gene therapy is a well-suited approach for the treatment of SMA due to the monogenic nature of the disease—meaning it’s caused by the deletion of or mutations in a single gene. AVXS-101 is our clinical-stage, proprietary gene therapy candidate of a one-time, intravenous treatment for SMA Type 1—designed to prevent further muscle degeneration caused by SMA through:

Delivery of a fully functional human SMN gene into target motor neuron cells
Production of sufficient levels of SMN protein required to improve motor neuron function
Rapid onset of effect in addition to … Read more